Pharmacokinetics and Pharmacodynamics of Pravastatin in Pediatric and Adolescent Cardiac Transplant Recipients on a Regimen of Triple Immunosuppression

[1]  T. Abe,et al.  Comparative Inhibitory Effects of Different Compounds on Rat Oatp1 (Slc21a1)- and Oatp2 (Slc21a5)-Mediated Transport , 2002, Pharmaceutical Research.

[2]  P. Neuvonen,et al.  Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia , 2003, Clinical pharmacology and therapeutics.

[3]  E. Trulock,et al.  The Registry of the International Society for Heart and Lung Transplantation: Sixth Official Pediatric Report--2003. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[5]  J. Egido,et al.  Anti-inflammatory and immunomodulatory effects of statins. , 2003, Kidney international.

[6]  W. März,et al.  Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. , 2002, International journal of clinical pharmacology and therapeutics.

[7]  E. Trulock,et al.  The registry of the international society for heart and lung transplantation: nineteenth official report-2002. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  E. Trulock,et al.  The Registry of the International Society for Heart and Lung Transplantation: Fifth Official Pediatric Report-2001 to 2002. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  James P. Wilson,et al.  FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis , 2002, The Annals of pharmacotherapy.

[10]  Yuichi Sugiyama,et al.  Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[11]  James P. Wilson,et al.  Rhabdomyolysis and HMG-CoA Reductase Inhibitors , 2001, The Annals of pharmacotherapy.

[12]  J. Kobashigawa.  Statins as immunosuppressive agents , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  J. R. Thompson,et al.  Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  A Johnston,et al.  Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration–Time Curve: Review of Current Algorithms , 2001, Therapeutic drug monitoring.

[15]  P. Morgan,et al.  Role of transport proteins in drug absorption, distribution and excretion , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  M. Jemal,et al.  Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. , 2000, Journal of pharmaceutical and biomedical analysis.

[17]  P. Macdonald,et al.  Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  U. Christians,et al.  Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? , 1998, Pharmacology & therapeutics.

[19]  P. Neuvonen,et al.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.

[20]  G. Steinbeck,et al.  Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. , 1997, Circulation.

[21]  U. Christians,et al.  Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.

[22]  H. Scheld,et al.  Graft vascular disease after heart transplantation. , 1997, European heart journal.

[23]  B. Kasiske,et al.  Hyperlipidemia in solid organ transplantation. , 1997, Transplantation.

[24]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[25]  J. Quion,et al.  Clinical Pharmacokinetics of Pravastatin , 1994, Clinical pharmacokinetics.

[26]  A. Gavazzi,et al.  Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. , 1993, Transplantation proceedings.

[27]  S. Hunt,et al.  Transplant coronary artery disease: histopathologic correlations with angiographic morphology. , 1991, Journal of the American College of Cardiology.

[28]  L. Stevenson,et al.  Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. , 1990, Circulation.

[29]  M. Quiñones,et al.  Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. , 1988, JAMA.

[30]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.